Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

What Was Tested

This registered phase 4 trial tested Semaglutide.

It will also learn about the effect of the combination treatment on body weight, body composition, blood lipids, oxidative stress, inflammation, metabolic control, insulin resistance and insulin secretion from pancreas, together with its safety profile.

It had three arms (groups): Oral Semaglutide Arm (active comparator), Empagliflozin Arm (active comparator) and Control Arm (no intervention).

The registry classes the interventions as drug.

More on the Plan

These medications primarily include sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).

Traditionally, treatment of T2D followed a stepwise intensification by adding antihyperglycemic drugs if optimal glycemic control was not achieved.

However, current American Diabetes Association guidelines recommend considering early combination therapy at treatment initiation, particularly at high baseline glycated hemoglobin (HbA1c) levels, to shorten the time to achieve glycemic goals.

In everyday clinical practice, however, treatment intensification is often delayed due to clinical inertia, even when glycemic control is suboptimal.

Who Took Part

90 planned participants were the target.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Diagnosed with type 2 diabetes for up to 2 years (prior to randomization);. Aged between 18 and 70 years, both sexes, of any race or ethnicity;. Signed informed consent to participate in the study.

The full record lists 5 inclusion and 23 exclusion criteria; among the exclusions: treatment at any time in the past with sglt2i, glp-1ra, or dpp-4 inhibitors;; insulin treatment for longer than 2 weeks in the past;; body mass index below 22 kg/m2 or bmi above 40 kg/m2;.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

It started in 2024-10-01 with completion listed for 2027-09.

It ran at 1 site in Slovenia.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Time in Range (TIR) (time frame: Period of 14 days prior to last study visit (week 26)).

It also tracked 22 secondary outcomes, for example Absolute Change in Time in Range (TIR), Absolute Change in Glycated hemoglobin (HbA1c), Time above Range (TAR), Time below Range (TBR), Time above Range (TAR) - Level 1 Hyperglycemia and Time above Range (TAR) - Level 2 Hyperglycemia.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 90 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.